Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report

Abstract

Hyperuricemia is associated with the progression of chronic kidney disease (CKD) and cardiovascular diseases. Topiroxostat, a selective xanthine oxidase inhibitor, effectively reduces serum uric acid (UA) levels and urinary albumin excretion (UAE) in CKD patients. A 50-year-old Japanese man was referred to our hospital due to albuminuria and hyperuricemia, and renal biopsy showed a typical hyperuricemic arteriolopathy. Treatment with topiroxostat decreased serum UA levels (9.2 mg/dL at baseline to 6.4 mg/dL after 6 months), UAE (388 to 88 mg/g.cr), and urinary level of liver-type fatty acid-binding protein (28.8 to 19.8 µg/g.cr). Interestingly, topiroxostat treatment was associated with a trend towards improved flow-mediated dilation (5.4 to 5.8%). These results suggested that topiroxostat in CKD patients with hyperuricemia is potentially effective, not only for ameliorating renal damages but also for improving endothelial function beyond its UA-lowering action.

Key Points

In the present case report, topiroxostat treatment in hyperuricemic patients with renal arteriolopathy reduced renal damage and increased flow-mediated dilation value.

Further studies are needed to assess the protective effects of topiroxostat treatment on renal and endothelial function in hyperuricemic patients.

Introduction

Elevated levels of serum uric acid (UA) are closely associated with an increased risk for mortality in patients with chronic kidney disease (CKD) [1]. Hyperuricemia has been shown to be a significant and independent risk factor for the development of kidney disease and albuminuria in the general Japanese population [2], and an animal study suggested that hyperuricemia may cause progression of hypertension and CKD by inducing pre-glomerular arteriolar damage, characterized by hyalinosis, wall thickening, and an increased number of smooth muscle cells [3]. Injuries to pre-glomerular arterioles cause glomerular hypertension and ischemia, which are universal risk factors for the progression of renal damage [3, 4]. A study of renal biopsies collected from hyperuricemic patients suggested that high levels of serum UA may be associated with the development of renal arteriolopathy and may play a pivotal role in the progression of renal injuries [5].

There are some evidence that UA-lowering treatment is effective for delaying the progression of CKD associated with hyperuricemia [6]. In studies of db/db mice, topiroxostat, a selective xanthine oxidase (XO) inhibitor, caused a dose-dependent decrease in both urinary albumin excretion (UAE) and plasma XO activity; however, in contrast, another XO inhibitor, febuxostat, showed no such effect [7]. In addition, topiroxostat 160 mg was reported to effectively and safely decrease serum UA levels and UAE in hyperuricemic patients with stage III CKD [8]. Taken together, these results suggest topiroxostat may have a renal protective effect over and above its UA-lowering action. In the present report, we describe a patient with renal biopsy-proven hyperuricemic arteriolopathy in whom topiroxostat reduced not only UAE but also urinary liver-type fatty acid-binding protein (L-FABP), a marker of tubulointerstitial injury, and flow-mediated dilation (FMD), a marker of endothelial dysfunction.

Case Presentation

A 50-year-old Japanese male was referred to our hospital due to albuminuria and hyperuricemia. At 40 years of age, the patient had been diagnosed with hyperuricemia (8.4 mg/dL) in another clinic but did not receive follow-up treatment at that time. Then, at 50 years of age, he visited the same clinic and was again diagnosed with hyperuricemia (9.0 mg/dl) and high UAE (390 mg/g.cr), leading to admission to our hospital for a detailed examination of CKD. He had no history of smoking or major diseases, excluding hyperuricemia, and no family history of renal diseases. Clinical examination and laboratory tests at admission showed the following characteristics: height 170 cm, weight 68 kg, blood pressure 130/82 mmHg, heart rate 70 beats/min, serum UA 9.2 mg/dL, UAE 388.6 mg/g.cr, urinary L-FABP 28.8 µg/g.cr (normal range <8.4 µg/g.cr), serum creatinine 1.32 mg/dL, estimated glomerular filtration ratio 46.6 mL/min/1.73 m², no hematuria, normal proteinemia (serum total protein 7.0 g/dL, serum albumin 4.2 g/dL), normoglycemia (fasting blood sugar 96 mg/dL, HbA1c 5.6%), and normal lipid profile (low-density lipoprotein cholesterol 126 mg/dL, triglycerides 96 mg/dL, high-density lipoprotein cholesterol 66 mg/dL). Plasma serology was negative for antinuclear antibody, antiglomerular basement membrane antibody, myeloperoxidase antineutrophil cytoplasmic antibody (ANCA), proteinase 3-ANCA, hepatitis C antibody, and hepatic B antigen. Serum complement and immunoglobulin levels were within normal limits, and the FMD value was 5.4% (normal range >6.0%).

A renal biopsy was performed on day 3 after admission. Renal histopathology showed renal arteriolar hyalinosis and arteriolar wall thickening, tubular atrophy, and interstitial fibrosis, but only minor changes in the glomeruli (Fig. 1). These findings were compatible with renal arteriolopathy related to hyperuricemia [5]. In addition, immunohistochemistry for deposition of immunoglobulin G (IgG), IgM, IgA, C3, and C1q were all negative. The patient was therefore diagnosed with hyperuricemic arteriolopathy. Because of its potential renal protective effect described earlier, topiroxostat treatment (160 mg/day) was initiated on day 7. The serial changes in laboratory data pre- and post-topiroxostat treatment are shown in Table 1. The patient’s serum UA level decreased from 9.2 to 7.4 mg/dL after 3 months and 6.4 mg/dL after 6 months, while UAE decreased from 388.6 to 288.2 mg/g.cr after 3 months and 88.4 mg/g.cr after 6 months. The urinary L-FABP level also decreased from 28.8 to 24.2 µg/g.cr after 3 months and 19.8 µg/g.cr after 6 months. In addition, FMD increased slightly from 5.4 to 5.6% after 3 months and 5.8% after 6 months. Other parameters, including blood pressure, renal function, and lipid profile, showed only minor changes during the 6-month treatment period. No adverse drug reaction was observed.

Fig. 1.

Histopathology of kidney specimens. a Vascular wall thickening and interstitial fibrosis are prominent features in the sections (PAS staining ×200). b Hyalinosis in the afferent arteriole (arrow) (PAS staining ×400). PAS periodic acid–Schiff

Table 1.

Serial changes in laboratory and clinical indices over the 6-month treatment period

Variables	Pre-treatment	After 3 months	After 6 months
Systolic/diastolic blood pressure, mmHg	130/82	128/80	128/80
Low-density lipoprotein cholesterol, mg/dL	126	124	122
High-density lipoprotein cholesterol, mg/dL	66	68	66
Triglyceride, mg/dL	98	100	100
Serum creatinine, mg/dL	1.32	1.30	1.28
Blood urea nitrogen, mg/dL	22	22	20
Uric acid, mg/dL	9.2	7.4	6.4
Urinary albumin excretion, mg/g.cr	388.6	288.2	88.4
Liver-type fatty acid-binding protein, µg/g.cr	28.8	24.2	19.8
Flow-mediated dilation, %	5.4	5.6	5.8

Discussion

The present case of hyperuricemia and biopsy-proven renal arteriolar injury is the first to demonstrate that treatment with topiroxostat has the ability to decrease serum UA, UAE, and urinary L-FABP levels, and increase FMD value.

Hyperuricemia is strongly associated with a wide range of complications, such as hypertension, metabolic syndrome, cardiovascular disease, and CKD [9–13]. UA-lowering therapy is therefore important to prevent or delay the progression of these diseases. Previous experimental animal studies demonstrated that hyperuricemia could cause progression of CKD by inducing pre-glomerular arteriolar damages, characterized by hyalinosis and wall thickening [3, 4]. Kohagura et al. [5] reported an association between UA levels in hyperuricemic CKD patients and parameters of renal arteriolopathy, such as hyalinosis and wall thickening. It is suggested that the association between hyperuricemia and renal arteriolar damages could potentially induce glomerular hypertension and resultant progression of CKD [5, 14]. It would therefore be anticipated that UA-lowering therapy should slow the progression of CKD and improve renal outcomes in patients with hyperuricemia and CKD [15]. Topiroxostat is a non-purine selective XO inhibitor approved in Japan as a UA-lowering agent [16]. High doses of topiroxostat (160 mg/day) were shown to reduce UAE and serum UA levels compared with placebo in patients with hyperuricemia and stage III CKD with or without gout [8]. It was also recently reported that urinary excretion of L-FABP was significantly lower in an animal model of adenine-induced renal injury treated with topiroxostat compared with animals treated with febuxostat [17]. Urinary L-FABP is approved as a clinical biomarker of tubular damage and may be a useful prognostic biomarker of progression to end-stage renal disease and the onset of cardiovascular disease in patients with CKD [18]. On the basis of these results, in the present case we decided to administer topiroxostat 160 mg/day, but not febuxostat.

A previous study provided an interesting insight in that an excess level of UA may have a direct effect on the cells that determine the structure of vessels [5]. In this regard, UA has been shown to promote proliferation of vascular smooth muscle cells and reduce nitric oxide, resulting in endothelial dysfunction [19]. On the other hand, Chen et al. [20] reported an interrelationship between multiple markers and pathways, leading to impaired endothelial function in patients with CKD. Given these relationships, there seems to be a pathological triangle between hyperuricemia, CKD, and endothelial dysfunction. However, some recent studies have reported conflicting results with decreased serum UA levels induced by allopurinol, a conventional XO inhibitor, increasing FMD in patients with stage II–IV CKD and plasma UA levels > 5.5 mg/dL [21]. In contrast, another study showed that allopurinol did not improve endothelial function in asymptomatic hyperuricemic patients with stage III CKD [22]. Therefore, it remains controversial whether UA-lowering therapy improves endothelial function in hyperuricemic patients with CKD. Moreover, the precise mechanisms by which XO inhibitors modulate endothelial function have yet to be elucidated. The present case of a patient treated with topiroxostat was the first to show an increase in the FMD value after 6 months of treatment; however, no data regarding whether there is a dose-dependent effect on endothelial function and whether XO inhibitors exert as a class effect are currently available. Recent randomized trials on post cardiac surgery hyperuricemic patients with or without CKD showed that febuxostat provided superior anti-inflammatory and renoprotective effects than allopurinol [23, 24]. A randomized trial to assess the effect of febuxostat on atherosclerosis and vascular function over 24 months is currently ongoing in Japan [25]. Furthermore, the ETUDE study group in Japan has also started a randomized study to clarify the renoprotective effect of topiroxostat and evaluate the safety of its serum UA level-lowering effect in patients with diabetic nephropathy and hyperuricemia [26]. Thus, increasing attention is being given to the protective effects of newer XO inhibitors on renal and cardiovascular systems beyond their UA-lowering action.

Conclusions

We report a case of a patient with CKD and biopsy-proven hyperuricemic-associated arteriolopathy in whom topiroxostat treatment was effective in reducing serum UA, UAE, and urinary L-FABP levels, and in increasing FMD value. This finding indicates that large-scale and long-term randomized trials are warranted to test the protective effects of topiroxostat treatment on renal and endothelial function in hyperuricemic patients.

Compliance with Ethical Standards

Funding

This case report was not supported by any funding bodies.

Conflicts of interest

Koichi Node has received honoraria from Boehringer Ingelheim, Daiichi Sankyo, Novartis, Astellas, Kowa, Bayer, Merck, Takeda, Pfizer, Mitsubishi Tanabe, TEIJIN, Sanofi, Kyowa Hakko Kirin, AstraZeneca; and research Grants from Astellas, AstraZeneca, Otsuka, Kyowa Hakko Kirin, Sanofi, Sanwa Kagaku Kenkyusho, Daiichi Sankyo, Sumitomo Dainippon, Takeda, Mitsubishi Tanabe, TEIJIN, Boehringer Ingelheim, Novartis, Pfizer, Bristol-Myers Squibb, and Merck. Atsushi Tanaka, Tsukasa Nakamura and Eiichi Sato declare no conflicts of interest.